|  |
| |
| Figure A. All three isoforms. Figure B. A ribbon diagram of the TL1A trimer. (Jin et al. BBRC 364:1, 2007). |
| |
Description | Hydrophobicity analysis of VEGI predicts a 13 amino acid hydrophobic region that follows the amino terminal segment of 12 amino acids, suggesting a structure characteristic of a type II transmembrane protein, with residues 26-174 constituting an extracellular domain analogous to domains found in other TNF family members. VEGI isoforms exhibit a carboxyl terminal domain of 151 amino acid residues, which is encoded by part of the fourth exon, termed IVb. The initially characterized VEGI isoform, designated VEGI-174, is encoded by the fourth exon (parts IVa and IVb) alone, which includes both the putative transmembrane domain and the conserved extracellular domain. There are two additional endothelial-specific transcripts of 7.5 and 2.0 kb, which encode peptides of 251 (VEGI-251) and 192 (VEGI-192) residues, respectively. The VEGI-251 and -192 isoforms differ in their amino terminal regions, but share the conserved 151-amino acid residue carboxy terminal domain. VEGI-251 possesses a putative secretory signal peptide and its overexpression causes apoptosis of endothelial cells and inhibition of tumor growth. |
|  |
| |
| Amino acid sequence alignment of three VEGI isoforms. The putative hydrophobic regions of VEGI-251 and VEGI-174 are underlined. Asterisk denotes the start of shared sequences for all three isoforms. |
| |
Expression | VEGI is specifically expressed in endothelial cells. Analysis of total RNA preparations from many cell lines and primary cell cultures by Northern blot analysis confirmed the specificity of VEGI expression, with only HUVEC and human venous endothelial cells demonstrating detectable levels of expression. Using multiple tissue Northern blots, the VEGI transcript was found in many adult human tissues, including placenta, lung, skeletal muscle, kidney, pancreas, spleen, prostate, small intestine, and colon, suggesting that the gene product may play a role in the function of a normal vasculature.The failure to detect the transcripts of this new gene in some of the human tissues probably is due to relatively small proportion of endothelial cells in these tissues. Using isoform-specific probes, we have determined that the distribution profiles of VEGI isoforms in human organs and tissues appear to be different. The 7.5 kb transcript encoding VEGI-251 was expressed at high levels in the placenta, kidney, lung and liver, whereas the 2 kb transcript corresponding to VEGI-174 was observed in liver, kidney, skeletal muscle and heart. VEGI-174 mRNA was more abundant in heart, skeletal muscle, pancreas, adrenal gland, and liver, while VEGI-251 was more abundant in fetal kidney and fetal lung. Overlapping expression of VEGI-251 and VEGI-174 mRNA was detected in prostate, salivary gland and placenta, whereas VEGI-192 mRNA was not readily detected by Northern blot. These expression patterns suggest the possibility of tissue or developmentally specific functions for VEGI isoforms. Alternatively, this expression pattern also supports the view that one VEGI isoform is the functional cytokine,while the others act in regulatory roles to modulate the activity of the active isoform. In this case, it is possible that the non-functional isoforms do not exist at the protein level. VEGI isoform expression has also been examined in cultured cells by RNase protection assay. All three known VEGI isoforms were detected in human endothelial cells, including coronary artery endothelial (HCAE), HUVE cells, and human microvascular endothelial (HMVE) cells. Very low levels are sometimes detected in adult bovine aortic endothelial (ABAE) cells. Little VEGI expression was detectable in human coronary artery smooth muscle (CASM) and mouse endothelioma bEND.3 cells. More than one isoform is detectable simultaneously, with VEGI-251 being the most abundant. The expression of this protein is inducible by TNF and IL-1 alpha, but not by gamma-interferon. |
Localisation | Endothelial cells and monocytes. However, VEGI was not expressed in either B or T cells. |
Function | VEGI is an endogenous inhibitor of angiogenesis produced largely by vascular endothelial cells and exerts a specific inhibitory activity on the proliferation of endothelial cells. VEGI enforces growth arrest of endothelial cells in G0 and early G1 phases of the cell cycle but induces apoptosis in proliferating endothelial cells. The MAPKs p38 and jun N-terminal kinase (JNK) are required for VEGI-mediated endothelial inhibition. Engineered overexpression of secreted VEGI by cancer cells or systemic administration of recombinant VEGI to tumor-bearing mice inhibits tumor growth in numerous tumor models. Recent studies show that VEGI helps modulate the immune system by activating T cells and stimulating dendritic cell maturation, suggesting that VEGI is directly involved in modulating the interaction between the endothelium and the immune system. Recombinant VEGI has an inhibitory activity on mouse bone marrow-derived EPCs in culture, preventing their differentiation toward endothelial cells. Interaction of TL1A with DR3 promotes T cell expansion during an immune response (Migone et al., 2002). |
Homology | VEGI exhibits 20-30% sequence homology to human TNF-alpha, TNF-beta, and the Fas ligand, similar to that among other TNF family members. |
TL1A both promotes and protects from renal inflammation and injury. |
Al-Lamki RS, Wang J, Tolkovsky AM, Bradley JA, Griffin JL, Thiru S, Wang EC, Bolton E, Min W, Moore P, Pober JS, Bradley JR. |
J Am Soc Nephrol. 2008 May;19(5):953-60. Epub 2008 Feb 20. |
PMID 18287561 |
|
Endothelial progenitor cells for postnatal vasculogenesis. |
Asahara T, Kawamoto A. |
Am J Physiol Cell Physiol. 2004 Sep;287(3):C572-9. (REVIEW) |
PMID 15308462 |
|
Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. |
Bamias G, Martin C 3rd, Marini M, Hoang S, Mishina M, Ross WG, Sachedina MA, Friel CM, Mize J, Bickston SJ, Pizarro TT, Wei P, Cominelli F. |
J Immunol. 2003 Nov 1;171(9):4868-74. |
PMID 14568967 |
|
Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. |
Bamias G, Mishina M, Nyce M, Ross WG, Kollias G, Rivera-Nieves J, Pizarro TT, Cominelli F. |
Proc Natl Acad Sci U S A. 2006 May 30;103(22):8441-6. Epub 2006 May 12. |
PMID 16698931 |
|
Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis. |
Bamias G, Siakavellas SI, Stamatelopoulos KS, Chryssochoou E, Papamichael C, Sfikakis PP. |
Clin Immunol. 2008 Nov;129(2):249-55. Epub 2008 Aug 30. |
PMID 18757243 |
|
The Death Receptor 3-TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis. |
Bull MJ, Williams AS, Mecklenburgh Z, Calder CJ, Twohig JP, Elford C, Evans BA, Rowley TF, Slebioda TJ, Taraban VY, Al-Shamkhani A, Wang EC. |
J Exp Med. 2008 Oct 27;205(11):2457-64. Epub 2008 Sep 29. |
PMID 18824582 |
|
Preparation and characterization of a novel chimeric protein VEGI-CTT in Escherichia coli. |
Cai J, Wei R, Cheng J. |
J Biomed Biotechnol. 2008;2008:564969. |
PMID 18769489 |
|
A novel secreted splice variant of vascular endothelial cell growth inhibitor. |
Chew LJ, Pan H, Yu J, Tian S, Huang WQ, Zhang JY, Pang S, Li LY. |
FASEB J. 2002 May;16(7):742-4. Epub 2002 Mar 26. |
PMID 11923219 |
|
Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. |
Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. |
Science. 2008 Jan 11;319(5860):195-8. |
PMID 18187653 |
|
VEGI-192, a new isoform of TNFSF15, specifically eliminates tumor vascular endothelial cells and suppresses tumor growth. |
Hou W, Medynski D, Wu S, Lin X, Li LY. |
Clin Cancer Res. 2005 Aug 1;11(15):5595-602. |
PMID 16061878 |
|
Purification and crystallization of recombinant human TNF-like ligand TL1A. |
Jin T, Kim S, Guo F, Howard A, Zhang YZ. |
Cytokine. 2007 Nov;40(2):115-22. Epub 2007 Oct 1. |
PMID 17905596 |
|
TNF superfamily member, TL1A, is a potential mucosal vaccine adjuvant. |
Kayamuro H, Yoshioka Y, Abe Y, Katayama K, Yoshida T, Yamashita K, Yoshikawa T, Hiroi T, Itoh N, Kawai Y, Mayumi T, Kamada H, Tsunoda S, Tsutsumi Y. |
Biochem Biophys Res Commun. 2009 Jul 3;384(3):296-300. Epub 2009 May 4. |
PMID 19406102 |
|
Vascular endothelial growth inhibitor (VEGI), an endogenous negative regulator of angiogenesis. |
Metheny-Barlow LJ, Li LY. |
Semin Ophthalmol. 2006 Jan-Mar;21(1):49-58. (REVIEW) |
PMID 16517446 |
|
TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. |
Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM, Wei P. |
Immunity. 2002 Mar;16(3):479-92. |
PMID 11911831 |
|
TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. |
Takedatsu H, Michelsen KS, Wei B, Landers CJ, Thomas LS, Dhall D, Braun J, Targan SR. |
Gastroenterology. 2008 Aug;135(2):552-67. Epub 2008 May 7. |
PMID 18598698 |
|
Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. |
Tan KB, Harrop J, Reddy M, Young P, Terrett J, Emery J, Moore G, Truneh A. |
Gene. 1997 Dec 19;204(1-2):35-46. |
PMID 9434163 |
|
The endothelial cell-produced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation. |
Tian F, Grimaldo S, Fujita M, Cutts J, Vujanovic NL, Li LY. |
J Immunol. 2007 Sep 15;179(6):3742-51. |
PMID 17785811 |
|
Inhibition of endothelial progenitor cell differentiation by VEGI. |
Tian F, Liang PH, Li LY. |
Blood. 2009 May 21;113(21):5352-60. Epub 2009 Mar 27. |
PMID 19329781 |
|
Modulation of endothelial cell growth arrest and apoptosis by vascular endothelial growth inhibitor. |
Yu J, Tian S, Metheny-Barlow L, Chew LJ, Hayes AJ, Pan H, Yu GL, Li LY. |
Circ Res. 2001 Dec 7;89(12):1161-7. |
PMID 11739281 |
|
TL1, a novel tumor necrosis factor-like cytokine, induces apoptosis in endothelial cells. Involvement of activation of stress protein kinases (stress-activated protein kinase and p38 mitogen-activated protein kinase) and caspase-3-like protease. |
Yue TL, Ni J, Romanic AM, Gu JL, Keller P, Wang C, Kumar S, Yu GL, Hart TK, Wang X, Xia Z, DeWolf WE Jr, Feuerstein GZ. |
J Biol Chem. 1999 Jan 15;274(3):1479-86. |
PMID 9880523 |
|
VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivo. |
Zhai Y, Ni J, Jiang GW, Lu J, Xing L, Lincoln C, Carter KC, Janat F, Kozak D, Xu S, Rojas L, Aggarwal BB, Ruben S, Li LY, Gentz R, Yu GL. |
FASEB J. 1999 Jan;13(1):181-9. |
PMID 9872942 |
|
Inhibition of angiogenesis and breast cancer xenograft tumor growth by VEGI, a novel cytokine of the TNF superfamily. |
Zhai Y, Yu J, Iruela-Arispe L, Huang WQ, Wang Z, Hayes AJ, Lu J, Jiang G, Rojas L, Lippman ME, Ni J, Yu GL, Li LY. |
Int J Cancer. 1999 Jul 2;82(1):131-6. |
PMID 10360832 |
|
Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. |
Zilberberg L, Shinkaruk S, Lequin O, Rousseau B, Hagedorn M, Costa F, Caronzolo D, Balke M, Canron X, Convert O, Lain G, Gionnet K, Goncalves M, Bayle M, Bello L, Chassaing G, Deleris G, Bikfalvi A. |
J Biol Chem. 2003 Sep 12;278(37):35564-73. Epub 2003 Jul 1. |
PMID 12837752 |
|